慢性肾脏病中RAS抑制剂与SGLT2抑制剂的药物管理:继续使用并重启治疗
本文为叙述性综述,探讨慢性肾脏病患者中RAS抑制剂和SGLT2抑制剂因不良反应、CKD进展、急性病、手术及造影剂而停药的情境,推荐在肾功能稳定后尽快重启,并反对因eGFR逐渐下降而停药。
要点
- AKI后肾功能稳定即重启RASi与SGLT2i。
- 轻中度高钾血症用噻嗪类利尿剂和SGLT2i避免停RASi。
- 择期手术前2-3天停SGLT2i,RASi术前停药未证实减少AKI。
核心结论
- 推荐在AKI后肾功能稳定时尽快重启RASi和SGLT2i。
- 不推荐因GFR逐渐下降而停用RASi或SGLT2i。
研究设计与样本
- 叙述性综述,探讨CKD患者中RASi和SGLT2i停药的情境与重启策略。
主要发现
- RASi相关AKI和高钾血症是停药原因之一。
- 对RASi治疗中轻中度高钾血症,主张用噻嗪类利尿剂和SGLT2i避免停RASi。
- 病日规则的证据不令人信服。
- 术前停RASi未显示减少AKI。
关键数值与推荐
- 涉及禁食或麻醉的择期操作前2-3天停用SGLT2i。
- 动脉内造影时不建议常规停SGLT2i,但可考虑临时停RASi,尤其晚期CKD或脱水患者。
- 事件后尽快重启RASi和SGLT2i;若两药均停用超过数天且有指征,建议错开启动。
临床怎么用
- AKI后肾功能稳定即重启RASi和SGLT2i。
- 轻中度高钾血症优先用噻嗪类利尿剂和SGLT2i而非停RASi。
- 择期手术前2-3天停SGLT2i,RASi停药决策可个体化。
- 造影后考虑临时停RASi(尤其晚期CKD或脱水),SGLT2i不常规停。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renin-angiotensin system inhibitors (RASis) and sodium-glucose co-transporter 2 inhibitors (SGLT2is) are the cornerstones of management for patients with chronic kidney disease (CKD). The use of these treatments is limited by frequent discontinuations, increasing the risk of death and compromising cardiovascular and renal health. This narrative review explores scenarios that lead to discontinuation: adverse effects (i.e. RASi-related acute kidney injury and hyperkalaemia), progression of CKD, acute illness, surgery and contrast administration. After AKI, we recommend restarting RASis and SGLT2is as soon as kidney function stabilises. For patients with mild-to-moderate hyperkalaemia on RASis, we advocate for thiazide-like diuretics and SGLT2is to avoid RASi discontinuation rather than routine dietary restrictions or potassium binders. We recommend against discontinuing RASis or SGLT2is when glomerular filtration rates decrease gradually. We review the evidence for sick-day rules and find it unconvincing. Withholding RASis before surgery has not been shown to reduce AKI. For low-risk procedures, the decision may be deferred to the anaesthetist. However, in settings where anaesthetists assess patients only shortly before surgery, or in high-risk cases, earlier multidisciplinary input is advised. We recommend stopping SGLT2is 2-3 days before elective procedures that involve fasting or anaesthesia. For the use of intra-arterial contrast, such as with coronary angiography, we do not recommend routinely withholding SGLT2is but we do suggest considering temporarily withholding RASis, especially in patients with advanced CKD or dehydration. We suggest promptly restarting RASis and SGLT2is after events; if both drugs have been withheld for more than a few days, and both are indicated, we suggest a staggered start. By reconciling, reviewing and thoughtfully prescribing medications, drug stewardship can maximize the time spent on these life-prolonging therapies, as long as this aligns with patients' goals of care.
引用
- Bouwmans P, Clase CM, Carrero JJ, et al. Drug stewardship for RAS inhibitors and SGLT2 inhibitors in chronic kidney disease: stay on, restart. Nephrol Dial Transplant. 2026. PMID: 41569016. doi:10.1093/ndt/gfag008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。